Dopamine D2 Receptors(D2R) Imaging in Nonfunctioning Pituitary Adenoma(NFPA)

• Status: Not yet recruiting
• Trial end date: 2022-01-31
• Target enrollment: 0
• Participant gender: All

Summary

To study the in vivo expression of dopamine D2 receptors in nonfunctioning pituitary adenoma and the predictive role of dopamine dopamine D2 receptors PET-MR imaging in the therapeutic effect of dopamine agonists（DA）.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Zhebao Wu
• Collaborators: Beijing Tiantan Hospital; Chinese PLA General Hospital; First Affiliated Hospital of Fujian Medical University; First Affiliated Hospital of Wenzhou Medical University; First Hospital of China Medical University; Huashan Hospital; Peking Union Medical College Hospital; Xinqiao Hospital of Chongqing
• Treatments: Dopamine; Dopamine Agents

Criteria

Inclusion Criteria:

1. Normal serum pituitary hormone levels or mild increase of serum prolactin.

2. Enhanced MRI shows a pituitary tumor and tumor diameter>1cm.

3. Aged between 18 and 65 years old, either sex.

4. Karnofsky performance status ≥ 70.

5. The patient has signed the informed consent.

Exclusion Criteria:

1. Patients concomitantly taking the psychotropic drugs.

2. Patients with parkinson disease and is taking dopaminergic agents.

3. Patients with pituitary adenoma who received Gamma knife treatment.

4. Pregnant or lactating women.

5. Patients with poor compliance, who cannot implement the program strictly.

6. History of allergic reactions attributed to compounds of similar chemical or biologic composition to cabergoline.

7. Patients with claustrophobia. -